INOVIO completes rolling BLA for INO-3107; Q3 net loss $45.5M, cash runway into Q2 2026

INOVIO PHARMACEUTICALS, INC.

2025-Q3 EPS reported -$2.12 vs consensus -$0.43 ▼ miss (-396.0%)

Completed rolling BLA submission for INO-3107 (RRP); priority review requested; potential FDA decision mid-2026.
Net loss of $45.5M ($0.87/share) versus $25.2M loss a year ago; operating loss improved to $21.2M from $27.3M.
Cash and short-term investments $50.8M as of Sept 30, 2025; estimated runway into Q2 2026 with Q4 cash burn ~$22M.
R&D expenses fell to $13.3M from $18.7M; G&A expenses $7.9M down from $8.6M year-over-year.
Phase 1 DMAb data for COVID-19 published in Nature Medicine; demonstrated durable antibody expression in humans.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.